Page 181 - Multidisipliner Covid 19

COVID-19 ve Akci¤erler

COVID-19 patients. Proceedings of the National Academy of Sciences
117 (17):9490-9496
41. https://www.fda.gov/vaccines-blood-biologics/investigational-new-
drug-ind-or-device-exemption-ideproces-cber/investigational-covid
19-convalescent-plasma-emergency-inds FIc-cpeI.
42. Turkish Ministry of Health Immune Plasma Guidelines UhdsgtE,
covid-19-immun-plazma-rehberi-12-nisan-2020 sonv1tineopdfpdf.
pdf?0&_tag1D61DB6867EF68EE9A7FE73C870D9BBA- 04AACC05C.
43. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment
in COVID_19: A single center experience. Journal of medical virology
44. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S,
Calcagno A, Cecchi I, Cinnirella G (2020) Pilot prospective open, sin-
gle-arm multicentre study on off-label use of tocilizumab in patients
with severe COVID-19. Clin Exp Rheumatol 38 (00)
45. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ,
Collaboration HAS (2020) COVID-19: consider cytokine storm syn-
dromes and immunosuppression. Lancet (London, England) 395
(10229):1033
46. McCreary EK PharmD; BCPS; BCIDP; and Pogue, JM COVID-19 Treat-
ment: A Review of Early and Emerging Options. In: Open Forum In-
fectious Diseases, ofaa105, 2020.
47. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti
D, Oltolini C, Castiglioni B, Din CT, Boffini N (2020) Interleukin-1
blockade with high-dose anakinra in patients with COVID-19, acute
respiratory distress syndrome, and hyperinflammation: a retrospective
cohort study. The Lancet Rheumatology
48. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E,
Oczkowski S, Levy MM, Derde L, Dzierba A (2020) Surviving Sepsis
Campaign: guidelines on the management of critically ill adults with
Coronavirus Disease 2019 (COVID-19). Intensive care medicine:1-34
49. Xie Y, Cao S, Li Q, Chen E, Dong H, Zhang W, Yang L, Fu S, Wang R
(2020) Effect of regular intravenous immunoglobulin therapy on prog-
nosis of severe pneumonia in patients with COVID-19. The Journal
of Infection
50. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong
W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the
recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research

180